Allergan to cut 1,500 employees in restructuring

Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals.

The Irvine, California, company said Monday it plans to trim about 1,500 employees and around 250 vacant positions as it restructures to focus on its “highest value opportunities.”

Allergan said its restructuring will yield annual pretax savings of about $475 million in 2015. It announced the cuts the same day it said second-quarter results trumped analyst expectations, as earnings grew 16 percent to $417.2 million.

“Today’s results demonstrate that we’re clearly on the right path,” Chairman and CEO David Pyott told analysts during a conference call. “The actions announced today will only accelerate our trajectory.”

Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management. The latest amounts to about $53 billion in cash and stock.

Valeant has promised cost-cutting and savings of its own if the two companies combine. Ackman, whose company owns a 9.7 percent stake in Allergan, told CNBC that shareholders had been asking for Allergan cost-cutting for some time. He said the reductions that the company announced Monday amounted to “cutting out fat you should have cut out a long time ago.”

“Allergan can only achieve so much as a stand-alone company,” he said.

Ackman has lined up nominees for Allergan’s board, and Pershing Square wants to hold a special meeting where Allergan shareholders can have a say in the buyout bid and on the company’s direction.

Allergan, which also makes the dry-eye treatment Restasis, has adopted a “poison pill” measure to block a takeover. Pyott said Monday that Valeant’s offer was “so far away from the intrinsic value of this company” that there was no reason for the drugmakers to have substantive talks.

Allergan and Valeant have feuded publicly over the possible takeover since April. In the latest twist, Valeant said Monday it has complained to both the Securities and Exchange Commission and authorities in the Canadian province of Quebec, where it is based, that Allergan has been making false statements about its business even though Valeant has publicly corrected it.

Valeant said the latest example of these statements involves the performance of contact lens maker Bausch + Lomb, which Valeant acquired last year.

“We can no longer tolerate unjustified attacks on Valeant’s business and strongly believe we are obligated to take action to protect Valeant shareholders from Allergan’s apparent attempts to mislead investors and manipulate the market for Valeant stock,” Valeant Chairman and CEO J. Michael Pearson said in a statement from the company.

An Allergan spokesman responded by email that the company stood by its comments.

“We call on Valeant to report complete and transparent details on its business on an ongoing basis,” the spokesman said. “At the end of the day, investors will make their own decisions.”

The drugmaker also said on Monday that it raised its forecast for adjusted 2014 earnings to between $5.74 and $5.80 per share from a range of $5.64 to $5.73 that it predicted in May. It expects Botox to deliver net sales ranging from $2.2 billion to $2.28 billion.

Botox is known best for its ability to smooth frown lines on aging foreheads, but it also is approved to treat neck spasms, eye muscle disorders, migraines and other conditions.

Shares of Allergan climbed 2.3 percent, or $3.90, to $171.30 Monday afternoon, while U.S.-traded shares of Valeant also were up 3 percent, or $3.69, to $125.66.

More in Herald Business Journal

More than 60 Boeing 737s per month: Can suppliers keep up?

There was lots of talk this week about the prudence and pressures of soaring production rates.

Developer proposes an 18-story building in Lynnwood

It would be the second-tallest in the county and include apartments with retail space.

Even as stock markets shook, many investors held steady

Older investors were buying stocks, but at a lower rate than their younger counterparts.

Snohomish County business licenses

PLEASE NOTE: Business license information is obtained monthly from the Washington Secretary… Continue reading

New Everett mayor speaks out about business in city, region

Q&A: Cassie Franklin on what can be done to get Boeing to build the 797 here and attract new industries.

Aerospace analyst explains how he’ll help state’s Boeing bid

Richard Aboulafia will deliver a report on Washington’s strengths and weaknesses in landing the 797.

Air passenger traffic growing faster than airplane capacity

“Our customers are in a good place,” a Boeing marketing executive says of the airlines.

JC Penney to close store at the Cascade Mall in Burlington

Eight store closures will result in about 480 job cuts, according to CNBC.

Budget: Lockheed gets almost as much as State Department

Boeing is in second place with annual sales of $26.5 billion in 2016.

Most Read